Fig. 1From: Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritisChanges in DAS28-ESR (a) and DAS-remission rate (b). Changes in CDAI (c) and CDAI-remission rate (d). DAS: disease activity score; ESR: erythrocyte sedimentation rate; CDAI: clinical disease activity indexBack to article page